非瓣膜性房颤复律与消融中直接口服抗凝药的当代管理
本综述检索PubMed和MEDLINE至2018年6月,汇总DOACs在房颤复律和导管消融中的证据。前瞻性试验提示DOACs与VKA疗效和安全性相似,复律可避免桥接,消融仅高危出血者需最小中断。围术期优势包括便捷、起效快、患者满意度高和潜在降低成本。
要点
- 复律时DOACs与VKA疗效安全性相似,可避免注射抗凝桥接。
- 房颤消融仅高出血风险者(如肾功能不全、药物相互作用)需最小中断抗凝。
- DOACs围术期优势包括便捷、起效快、患者满意度高和潜在降低成本。
核心结论
- 前瞻性试验提示DOACs在复律和房颤消融中与VKA疗效和安全性相似。
- 复律时使用DOACs可避免注射抗凝药重叠桥接。
- 消融时仅最高出血风险者(如肾功能不全、药物相互作用)可能需要最小中断抗凝。
研究设计与样本
- 检索PubMed和MEDLINE从建库至2018年6月,纳入成人(>18岁)复律或房颤导管消融中比较DOACs与VKA的研究。
- 共识别4项回顾性研究和3项前瞻性试验比较DOACs与VKA在复律患者中的表现,以及3项前瞻性研究在房颤导管消融患者中的表现。
- 还批判性审查了观察性数据和荟萃分析。
主要发现
- 前瞻性试验提示DOACs在复律和房颤消融中与VKA传统治疗(伴或不伴桥接)疗效和安全性相似。
- 复律患者使用DOACs可避免注射抗凝药重叠。
- 房颤消融中仅最高出血风险者(如肾功能不全和药物相互作用可能增加抗凝药蓄积风险)可能需要最小中断抗凝。
临床怎么用
- 复律时可使用DOACs而无需注射抗凝桥接。
- 房颤消融前对高出血风险者(如肾功能不全、药物相互作用)考虑最小中断DOACs。
- DOACs围术期优势包括便捷、快速可预测起效、患者满意度提高和潜在降低成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As overall prevalence of atrial fibrillation (AF) continues to rise, the number of patients who undergo ablation, or electrical/chemical cardioversion, to restore normal sinus rhythm continues to increase as well. As direct oral anticoagulants (DOACs) have continued to be incorporated into clinical practice for long-term anticoagulation for AF, experience with how best to manage use of DOACs during electrophysiologic procedures is evolving. This review is intended to provide health care providers with a summary of current evidence regarding the use of DOACs during cardioversion and catheter ablation and provide key considerations for their use during such electrophysiologic procedures. PubMed and MEDLINE were searched from inception through June 2018 for studies in humans comparing DOACs alone or against vitamin K antagonists (VKAs) in adult patients (> 18 yrs) who underwent cardioversion or AF catheter ablation using the following key words: "rivaroxaban," "dabigatran," "apixaban," "edoxaban," "non-vitamin K antagonists," "direct or new oral anticoagulants," "warfarin," "vitamin K antagonists," "cardioversion," "ablation of atrial fibrillation," "uninterrupted," and "catheter ablation." Four retrospective studies and three prospective trials comparing DOACs with VKA in patients undergoing cardioversion and three prospective studies in patients undergoing catheter ablation for AF were identified. Observational data and meta-analyses were also critically reviewed. Prospective trials to date suggest similar efficacy and safety with using DOACs in the setting of cardioversion and AF ablation compared to traditional therapy with VKA, with or without bridging. Injectable anticoagulant overlap can be avoided in patients receiving DOACs in the setting of cardioversion for AF. Minimal interruption in anticoagulation may be only necessary for AF ablation in those with highest bleeding risk, such as in renal dysfunction and where drug-drug interactions may increase risk for anticoagulant accumulation. Periprocedural advantages of DOACs include convenience, rapid and predictable onset of effect, improved patient satisfaction, and potential for reduced costs.
引用
- Trujillo TC, Dobesh PP, Crossley GH, et al. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation. Pharmacotherapy. 2019. PMID: 30548542. doi:10.1002/phar.2205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。